The estimated Net Worth of Kevin Lorenz is at least $449 Tisíc dollars as of 1 January 2021. Mr. Lorenz owns over 50,000 units of Fortress Biotech Inc stock worth over $377,664 and over the last 5 years he sold FBIO stock worth over $0. In addition, he makes $70,950 as Independent Director at Fortress Biotech Inc.
Sign up
Mr. Lorenz FBIO stock SEC Form 4 insiders trading
Kevin has made over 2 trades of the Fortress Biotech Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of FBIO stock worth $88,000 on 1 January 2021.
The largest trade he's ever made was buying 50,000 units of Fortress Biotech Inc stock on 1 January 2021 worth over $88,000. On average, Kevin trades about 20,000 units every 73 days since 2020. As of 1 January 2021 he still owns at least 214,582 units of Fortress Biotech Inc stock.
You can see the complete history of Mr. Lorenz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kevin Lorenz biography
Kevin L. Lorenz J.D. serves as Independent Director of the Company. Mr. Lorenz has been Chief Investment Officer, Senior Vice President, Treasury & Private Investments at the Katz Group in the family office of Daryl Katz, which has operations in sports and entertainment, real estate and public and private investments. Mr. Lorenz works directly with the principal of the Katz Group to oversee the design, implementation and monitoring of the overall investment strategy for public and private passive investments. Prior to joining the Katz Group, Mr. Lorenz was Director, Ultra High Net Worth (“UHNW”) Private Client Business at Credit Suisse Securities, LLC from 2009-2015, where he was selected to expand Credit Suisse’s UHNW private client business into Canada. From 2004 to 2009, Mr. Lorenz was the Director, UHNW Management Group at UBS Financial Services, Inc., where he was a key contributor to the formation and development of the company’s first dedicated UBS UHNW office. Earlier in his career, he held positions of increasing responsibility at Merrill Lynch Pierce Fenner & Smith, Inc. and the Office of the Comptroller of the Currency, an independent bureau within the U.S. Department of the Treasury that charters, regulates and supervises all national banks and thrift institutions. Mr. Lorenz holds a J.D. from George Mason University Antonin Scalia Law School, an M.B.A. from Benedictine University and a B.S. in economics from Illinois State University.
What is the salary of Kevin Lorenz?
As the Independent Director of Fortress Biotech Inc, the total compensation of Kevin Lorenz at Fortress Biotech Inc is $70,950. There are 12 executives at Fortress Biotech Inc getting paid more, with Robyn Hunter having the highest compensation of $1,798,070.
How old is Kevin Lorenz?
Kevin Lorenz is 55, he's been the Independent Director of Fortress Biotech Inc since 2019. There are 9 older and 1 younger executives at Fortress Biotech Inc. The oldest executive at Fortress Biotech Inc is Malcolm Hoenlein, 76, who is the Independent Director.
What's Kevin Lorenz's mailing address?
Kevin's mailing address filed with the SEC is C/O FORTRESS BIOTECH, INC., 1111 KANE CONCOURSE SUITE 301, BAY HARBOR ISLANDS, FL, 33154.
Insiders trading at Fortress Biotech Inc
Over the last 9 years, insiders at Fortress Biotech Inc have traded over $826,952 worth of Fortress Biotech Inc stock and bought 6,309,522 units worth $9,160,045 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss a George Avgerinos. On average, Fortress Biotech Inc executives and independent directors trade stock every 77 days with the average trade being worth of $271,550. The most recent stock trade was executed by Lindsay A Md Rosenwald on 11 July 2024, trading 5,000 units of FBIO stock currently worth $37,400.
What does Fortress Biotech Inc do?
fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
What does Fortress Biotech Inc's logo look like?
Complete history of Mr. Lorenz stock trades at Fortress Biotech Inc
Fortress Biotech Inc executives and stock owners
Fortress Biotech Inc executives and other stock owners filed with the SEC include:
-
Robyn Hunter,
Chief Financial Officer, Treasurer, Secretary -
Michael Weiss,
Executive Vice Chairman - Strategic Development, Director -
Lindsay Rosenwald,
Executive Chairman of the Board, President, Chief Executive Officer -
Robyn M. Hunter,
CFO, Treasurer & Corp. Sec. -
Dr. Lindsay Allan Rosenwald,
Exec. Chairman, Pres & CEO -
Michael S. Weiss Esq.,
Vice Chairman & Exec. Vice Chairman of Strategic Devel. -
George Avgerinos,
Senior Vice President - Biologics Operations -
Eric Rowinsky,
Co-Vice Chairman and Director -
J. Jay Lobell,
Independent Director -
Dov Klein,
Independent Director -
Jimmie Harvey,
Independent Director -
Malcolm Hoenlein,
Independent Director -
Kevin Lorenz,
Independent Director -
Jaclyn Jaffe,
IR Contact Officer -
Dr. Thomas F. Schaible,
Project Leader of Inflammatory Bowel Disease -
David Jin,
Chief Financial Officer -
Lucy Lu,
Director